Suppr超能文献

痔病核心结局集(COS)制定方案:一项国际德尔菲研究

Protocol for the development of a Core Outcome Set (COS) for hemorrhoidal disease: an international Delphi study.

作者信息

van Tol R R, Melenhorst J, Dirksen C D, Stassen L P S, Breukink S O

机构信息

Department of Surgery, Maastricht University Medical Centre, P. Debelaan 25, 6229 HX, Maastricht, the Netherlands.

Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands.

出版信息

Int J Colorectal Dis. 2017 Jul;32(7):1091-1094. doi: 10.1007/s00384-017-2833-5. Epub 2017 May 13.

Abstract

PURPOSE

Over the last decade, many studies were performed regarding treatment options for hemorrhoidal disease. Randomised controlled trials (RCTs) should have well-defined primary and secondary outcomes. However, the reported outcome measures are numerous and diverse. The heterogeneity of outcome definition in clinical trials limits transparency and paves the way for bias. The development of a core outcome set (COS) helps minimizing this problem. A COS is an agreed minimum set of outcomes that should be measured and reported in all clinical trials of a specific disease. The aim of this project is to generate a COS regarding the outcome of treatment after hemorrhoidal disease.

METHODS

A Delphi study will be performed by an international steering group healthcare professionals and patients with the intention to create a standard outcome set for future clinical trials for the treatment of hemorrhoidal disease. First, a literature review will be conducted to establish which outcomes are used in clinical trials for hemorrhoidal disease. Secondly, both healthcare professionals and patients will participate in several consecutive rounds of online questionnaires and a face-to-face meeting to refine the content of the COS.

DISCUSSION

Development of a COS for hemorrhoidal disease defines a minimum outcome-reporting standard and will improve the quality of research in the future.

摘要

目的

在过去十年中,针对痔病的治疗方案开展了许多研究。随机对照试验(RCT)应有明确界定的主要和次要结局。然而,所报告的结局指标众多且各异。临床试验中结局定义的异质性限制了透明度,并为偏倚埋下了隐患。核心结局集(COS)的制定有助于最大限度地减少这一问题。COS是在特定疾病的所有临床试验中都应测量和报告的一组商定的最小结局指标。本项目的目的是生成一个关于痔病治疗结局的COS。

方法

一个由医疗保健专业人员和患者组成的国际指导小组将开展一项德尔菲研究,旨在为未来痔病治疗的临床试验创建一个标准结局集。首先,将进行文献综述,以确定在痔病临床试验中使用了哪些结局指标。其次,医疗保健专业人员和患者都将参与连续几轮的在线问卷调查以及一次面对面会议,以完善COS的内容。

讨论

痔病COS的制定确定了一个最小结局报告标准,并将在未来提高研究质量。

相似文献

引用本文的文献

本文引用的文献

10
Hemorrhoids: from basic pathophysiology to clinical management.痔疮:从基础病理生理学到临床管理。
World J Gastroenterol. 2012 May 7;18(17):2009-17. doi: 10.3748/wjg.v18.i17.2009.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验